Status and phase
Conditions
Treatments
About
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female 18-65 years of age (inclusive)
Diagnosed with IBS based on the following criteria (Rome III criteria):
Symptom onset at least 6 months prior to diagnosis, and
Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and
Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:
Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal